Stockreport

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD [Yahoo! Finance]

Cingulate Inc.  (CING) 
PDF CTx-1301 Could Benefit 60% of ADHD Patients Currently Using Immediate-Release Booster Doses Advancing Discussions with Commercialization Partners Ready to Engage wi [Read more]